$XBI $138.54 -6%
Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$OMER -1% Dosing of patients with narsoplimab for covid-19 started earlier this month. source
$AZN -3% Update on validating covid-19 data announced yesterday. source
Pipeline Updates
$ORMP +5% Initiates ph 3 oral insulin study under FDA approved protocol. source
$PGEN -6% Fist patient dosed for PRGN-2012 in recurrent respiratory papillomatosis (RRP). source
$LCTX -1% Interim results from ongoing ph 1/2a study of OpRegen. source
$AKRO -4% First patient randomized for dosing in ph 2b study of efruxifermin in NASH. source
$VTVT 6% Patent 10,952,993 issued for TTP399. source
$ASND -4% Data from 6-mo open-label ph 2 study of TransCon. source
$FREQ -78% Topline data from ph 2a study for FX-322. source
$IDYA -2% Dose expansion in ph 1/2 study of IDE196 and binimetinib. source
Financial Updates
$PRTA -12% Public offering. source
$XOMA -4% purchased future milestones and royalties associated with licenses for DAY101 and vosaroxin. source
Comments